Results from cohort 4 of the phase 2 SunRISe-1 trial showed TAR-200 elicited a 6- and 9-month DFS rate of 85.3% and 81.1%, respectively, in BCG-unresponsive NMIBC.
Joseph Jacob, MD, MCR
Advertisement
Articles by Joseph Jacob, MD, MCR
Advertisement
Latest Updated Articles
TAR-200 Might Be “Best in Class” for BCG-Unresponsive High-Risk NMIBCPublished: May 6th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?
3
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
4
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer
5
